From bloodjournal.hematologylibrary.org at Dana-Farber Cancer Institute on August 23, 2011. For personal use only: Prepublished online June 8, 2011; doi:blood

First Page		Document Content
Date: 2011-08-23 09:56:20 Pyrimidines Piperazines Pyridines Orphan drugs Chronic myeloid leukemia Chronic myelogenous leukemia Imatinib Philadelphia chromosome Nilotinib Tyrosine-kinase inhibitor ABL Bcr-Abl tyrosine-kinase inhibitor		From bloodjournal.hematologylibrary.org at Dana-Farber Cancer Institute on August 23, 2011. For personal use only: Prepublished online June 8, 2011; doi:blood Add to Reading List Source URL: michorlab.dfci.harvard.edu Download Document from Source Website File Size: 868,05 KB Share Document on Facebook

	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl DocID: 1pViD - View Document
	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1pE9A - View Document
	From bloodjournal.hematologylibrary.org at Dana-Farber Cancer Institute on August 23, 2011. For personal use only: Prepublished online June 8, 2011; doi:blood DocID: 1nEJu - View Document
	Microsoft Wordfile00 DocID: 1nCHs - View Document
	SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid DocID: 1fBTU - View Document